Karina I Konovalova, Michael M Shishkin, Rinat R Faizrakhmanov, Dilara B Babaeva
{"title":"Staged surgical treatment of complicated initial cataract in patients with advanced proliferative diabetic retinopathy.","authors":"Karina I Konovalova, Michael M Shishkin, Rinat R Faizrakhmanov, Dilara B Babaeva","doi":"10.18240/ijo.2025.10.10","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy of second-stage phacoemulsification (PE) of complicated initial cataract after vitreoretinal surgery (VRS) in patients with advanced proliferative diabetic retinopathy (PDR).</p><p><strong>Methods: </strong>Totally 216 patients with PDR and complicated initial cataract who underwent surgery were included. These patients were divided into four groups according to their management. In the 1<sup>st</sup> group patients were subjected to a two-step surgical procedure: VRS with silicone oil tamponade was performed as the first step, followed by the second step, PE+intraocular lens (IOL) implantation+silicone oil removal. In the 2<sup>nd</sup> group PE was performed simultaneously with VRS and silicone oil tamponade. The second step differed in the removal of silicone oil from the vitreous cavity. Patients Ia (<i>n</i>=17) and IIa (<i>n</i>=17) subgroups had their tear liquid samples being examined before surgery and on the 2<sup>nd</sup> day after the 1<sup>st</sup> phase. In subgroups Ib and IIb, an angiogenesis inhibitor was implanted 10-14d before VRS at a dose of 0.5 mg once. In the 3<sup>rd</sup> group patients were subjected to a two-step surgical procedure: VRS with gas tamponade performed as the 1<sup>st</sup> step in their treatment; followed by the 2<sup>nd</sup> step, PE and the IOL implantation. In the 4<sup>th</sup> group PE performed simultaneously with VRS with gas tamponade.</p><p><strong>Results: </strong>Patients in subgroup Ia and group III had better functional results than those in subgroup IIa and group IV, respectively (<i>P</i><0.001). More marked inflammatory response (2-3 points) was statistically significant in patients of the IIa subgroup (<i>P</i><0.001) and group IV (<i>P</i><0.001) in comparison with the patients in the Ia and group III respectively. The IIa subgroup (<i>n</i>=9; 14.5%) showed higher incidence of neovascular glaucoma (NVG) than the Ia (<i>n</i>=2; 3.2%), <i>P</i>=0.027. There also was a higher rate of NVG in group IV (<i>n</i>=6; 19.3%) compared to group III (<i>n</i>=1; 3.1%), <i>P</i>=0.04. Subgroup IIa revealed a 2 to 2.5 times higher concentration of interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), and inter-cellular adhesion molecule 1 (ICAM-1) compared to subgroup Ia.</p><p><strong>Conclusion: </strong>PE of initial cataract at the second stage after VRS in patients with advanced PDR provides a sparing approach to surgical treatment in this category of patients and allows to improve anatomical and functional results of VRS. In addition, it contributes to reduction of number and severity of postoperative complications.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 10","pages":"1888-1893"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454019/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.10.10","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To evaluate the efficacy of second-stage phacoemulsification (PE) of complicated initial cataract after vitreoretinal surgery (VRS) in patients with advanced proliferative diabetic retinopathy (PDR).
Methods: Totally 216 patients with PDR and complicated initial cataract who underwent surgery were included. These patients were divided into four groups according to their management. In the 1st group patients were subjected to a two-step surgical procedure: VRS with silicone oil tamponade was performed as the first step, followed by the second step, PE+intraocular lens (IOL) implantation+silicone oil removal. In the 2nd group PE was performed simultaneously with VRS and silicone oil tamponade. The second step differed in the removal of silicone oil from the vitreous cavity. Patients Ia (n=17) and IIa (n=17) subgroups had their tear liquid samples being examined before surgery and on the 2nd day after the 1st phase. In subgroups Ib and IIb, an angiogenesis inhibitor was implanted 10-14d before VRS at a dose of 0.5 mg once. In the 3rd group patients were subjected to a two-step surgical procedure: VRS with gas tamponade performed as the 1st step in their treatment; followed by the 2nd step, PE and the IOL implantation. In the 4th group PE performed simultaneously with VRS with gas tamponade.
Results: Patients in subgroup Ia and group III had better functional results than those in subgroup IIa and group IV, respectively (P<0.001). More marked inflammatory response (2-3 points) was statistically significant in patients of the IIa subgroup (P<0.001) and group IV (P<0.001) in comparison with the patients in the Ia and group III respectively. The IIa subgroup (n=9; 14.5%) showed higher incidence of neovascular glaucoma (NVG) than the Ia (n=2; 3.2%), P=0.027. There also was a higher rate of NVG in group IV (n=6; 19.3%) compared to group III (n=1; 3.1%), P=0.04. Subgroup IIa revealed a 2 to 2.5 times higher concentration of interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), and inter-cellular adhesion molecule 1 (ICAM-1) compared to subgroup Ia.
Conclusion: PE of initial cataract at the second stage after VRS in patients with advanced PDR provides a sparing approach to surgical treatment in this category of patients and allows to improve anatomical and functional results of VRS. In addition, it contributes to reduction of number and severity of postoperative complications.
期刊介绍:
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.